IRIS
MORE', Sonia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.089
AS - Asia 1.096
EU - Europa 855
SA - Sud America 337
Continente sconosciuto - Info sul continente non disponibili 139
AF - Africa 79
OC - Oceania 3
Totale 4.598
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.972
IT - Italia 307
VN - Vietnam 303
BR - Brasile 263
SG - Singapore 263
CN - Cina 194
RU - Federazione Russa 169
HK - Hong Kong 157
DE - Germania 85
FR - Francia 71
FI - Finlandia 51
CA - Canada 47
IN - India 39
GB - Regno Unito 36
CI - Costa d'Avorio 35
BD - Bangladesh 34
AR - Argentina 33
MX - Messico 29
NL - Olanda 28
IE - Irlanda 25
AT - Austria 18
JP - Giappone 16
CO - Colombia 12
MA - Marocco 12
IQ - Iraq 11
SV - El Salvador 11
ZA - Sudafrica 11
CR - Costa Rica 10
ID - Indonesia 10
SE - Svezia 10
EC - Ecuador 9
SA - Arabia Saudita 9
TR - Turchia 9
PL - Polonia 8
UA - Ucraina 8
VE - Venezuela 8
AE - Emirati Arabi Uniti 7
LT - Lituania 7
UZ - Uzbekistan 7
ES - Italia 6
HN - Honduras 6
PY - Paraguay 6
CW - ???statistics.table.value.countryCode.CW??? 5
PK - Pakistan 5
HU - Ungheria 4
KE - Kenya 4
KR - Corea 4
MY - Malesia 4
PE - Perù 4
SN - Senegal 4
TN - Tunisia 4
AU - Australia 3
BE - Belgio 3
DK - Danimarca 3
GT - Guatemala 3
JO - Giordania 3
NI - Nicaragua 3
TH - Thailandia 3
TW - Taiwan 3
BH - Bahrain 2
CH - Svizzera 2
DZ - Algeria 2
EG - Egitto 2
GP - Guadalupe 2
HR - Croazia 2
IS - Islanda 2
NP - Nepal 2
PH - Filippine 2
PR - Porto Rico 2
RO - Romania 2
TT - Trinidad e Tobago 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GR - Grecia 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MT - Malta 1
MU - Mauritius 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 4.464
Salva come PNG Salva come JPEG
Città #
Ashburn 461
Dallas 379
Singapore 157
Hong Kong 154
Council Bluffs 152
San Jose 145
Ho Chi Minh City 110
Hanoi 61
Boardman 50
Los Angeles 44
Beijing 40
The Dalles 39
Munich 36
Abidjan 35
Helsinki 35
Lauterbourg 35
New York 30
São Paulo 30
Moscow 27
Phoenix 27
Rome 26
Santa Clara 26
Dublin 25
Milan 25
Hefei 23
Chandler 22
Denver 18
Frankfurt am Main 18
Chicago 17
Montreal 17
Nuremberg 17
Buffalo 16
Da Nang 16
Turku 15
Mexico City 13
Orem 12
Brooklyn 11
Amsterdam 10
Ancona 10
Atlanta 10
Chennai 10
Guangzhou 10
Haiphong 10
San Salvador 10
Tokyo 10
Turin 10
Biên Hòa 9
Bologna 9
Bari 8
Warsaw 8
Houston 7
Hải Dương 7
Johannesburg 7
Lynnwood 7
Milwaukee 7
Rio de Janeiro 7
San Francisco 7
Toronto 7
Xi'an 7
Can Tho 6
Lawrence 6
Manchester 6
Newark 6
Princeton 6
Salt Lake City 6
San José 6
Shenzhen 6
Tashkent 6
Vilnius 6
Baghdad 5
Boston 5
Cartagena 5
Curitiba 5
Fairfield 5
Falconara Marittima 5
Jiujiang 5
London 5
Naples 5
North Charleston 5
Poplar 5
Porto Alegre 5
Redmond 5
Seattle 5
Thái Nguyên 5
Washington 5
Willemstad 5
Belo Horizonte 4
Bowling Green 4
Buenos Aires 4
Camden 4
Caracas 4
Columbus 4
Dakar 4
Harper Woods 4
Huế 4
Miami 4
Mumbai 4
New Delhi 4
Osimo 4
Pescara 4
Totale 2.752
Salva come PNG Salva come JPEG
Nome #
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial 227
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations 164
Real‐world assessment of treatment patterns and outcomes in patients with relapsed‐refractory multiple myeloma in an Italian haematological tertiary care centre 157
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab‐Refractory Multiple Myeloma Patients: A Multicenter Real‐World Study 149
POOR RESPONSE TO FIRST BNT162B2 SARS-COV-2 VACCINE DOSE IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT 149
Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study 145
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 141
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 135
Current Main Topics in Multiple Myeloma 134
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 134
Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia 126
Editorial: Reviews in hematologic malignancies 120
Developments in consolidation and maintenance strategies in post-remission multiple myeloma 120
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 119
Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis 119
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma 116
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 115
AL amyloidosis: an overview on diagnosis, staging system, and treatment 115
A rare case of solitary plasmacytoma mimicking submucosal lesion of ascending colon: a case report and literature review 114
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment 113
Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience 112
Clinicians’ Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy 111
Long-Term Survival with Multiple Myeloma: An Italian Experience 110
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety 110
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights 109
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy 107
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 104
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences 104
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 102
Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma Group 99
Plasma cell leukemia: first diagnostic approach in the laboratory|Leucemia plasmacellulare: primo inquadramento diagnostico in laboratorio 92
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management 90
Monoclonal antibodies: Leading actors in the relapsed/refractory multiple myeloma treatment 90
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients 80
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 79
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments 78
Sequential Bispecific Antibodies in Functional and Clinical High Risk Multiple Myeloma, Manifesting with Extramedullary Disease at Relapse: A Case Report 76
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy 64
Novel Experimental Drugs for Treatment of Multiple Myeloma 63
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice? 32
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application 22
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy 22
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone 15
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape 15
Totale 4.598
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.199
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.199
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202232 0 0 0 0 0 0 10 0 6 2 7 7
2022/202372 8 7 8 3 5 3 0 3 16 0 13 6
2023/2024190 22 3 7 5 22 6 3 6 8 8 26 74
2024/2025783 65 36 20 11 16 77 86 29 162 87 89 105
2025/20262.920 215 230 461 300 267 213 459 203 178 231 79 84
2026/2027601 118 97 121 265 0 0 0 0 0 0 0 0
Totale 4.598